Cytokinetics (CYTK) Q2 2026 earnings review
MYQORZO Launch Accelerates as Balance Sheet is Fortified
Cytokinetics is executing a textbook commercial transition. While headline total revenue dropped 57% YoY to $28.6M (due to a tough comparison against a one-time $64.4M milestone in 25Q2), the underlying signal is overwhelmingly positive: MYQORZO net product sales surged sequentially to $25.3M from $4.8M in Q1. Simultaneous positive Phase 3 data for ACACIA-HCM paves the way for a massive label expansion into non-obstructive HCM (nHCM). Management smartly capitalized on this momentum, raising $760M in equity to swell the cash balance to $1.7B. Guidance for operating expenses was bumped up, reflecting accelerating investments to capture the nHCM opportunity in 2027.
🐂 Bull Case
MYQORZO adoption is accelerating rapidly. Patients dispensed more than doubled sequentially to ~1,500, with over 80% converting to paid prescriptions, proving strong payer access and clinical demand.
Positive ACACIA-HCM data essentially de-risks the nHCM indication. Submitting the sNDA in Q4 2026 sets up MYQORZO to potentially be the first and only therapy for the entire HCM spectrum.
🐻 Bear Case
Despite the massive $1.7B cash pile, operating expenses are steep. Management raised FY26 GAAP combined expense guidance to $860M-$890M. Profitability remains years away.
Total Q2 revenue of $28.6M is a 57% YoY decline. While driven by lump-sum milestone comps, the company remains highly dependent on a single asset's commercial ramp to bridge the valuation gap.
⚖️ Verdict: 🟢
Bullish. The commercial launch metrics are excellent, the clinical de-risking of the nHCM market is a massive value unlock, and the $1.7B cash runway removes any near-term financing overhang.
Key Themes
MYQORZO US Uptake is Accelerating
The US launch metrics are exceptional for a first-time commercial organization. Unique prescribing HCPs grew from 275 in Q1 to over 700 in Q2. Dispensed patients jumped from 680 to approximately 1,500. Crucially, over 80% of patients on therapy are on a paid prescription, indicating that the company's payer access strategy and 'Corzo & You' support programs are functioning flawlessly.
ACACIA-HCM Data Unlocks New Market
The Phase 3 ACACIA-HCM trial met both dual primary endpoints (KCCQ Clinical Summary Score and peak VO2) with statistical significance, alongside key secondary endpoints. With no new safety signals and a Q4 2026 sNDA submission planned, this fundamentally expands aficamten's Total Addressable Market into non-obstructive HCM, an area with zero approved therapies.
International Expansion Gaining Traction
European commercialization is officially underway with the June launch in Germany (contributing $2.3M in initial stocking revenue). Furthermore, MYQORZO was approved by the UK's MHRA with a simultaneous recommendation by NICE for use in England and Wales. The submission of 10 HTA dossiers across Europe sets up a broad rollout targeting 5+ additional markets by 1H 2027.
Operating Expense Guidance Bump
The cost of building a global cardiovascular franchise is rising. Management increased FY26 combined GAAP R&D and SG&A guidance from $830-$870M to $860-$890M. This acceleration is explicitly tied to commercial readiness investments for the potential 2027 nHCM launch.
Total Revenue Contracts Due to Milestone Comparisons
A potential optical red flag for algorithmic investors: Total Q2 revenue dropped from $66.8M to $28.6M YoY. This reversing trend is entirely due to the absence of the $64.4M in license and milestone revenue recognized in 25Q2 (primarily from the Bayer Japan partnership). While product sales are surging, the company must outgrow these lumpy legacy comps.
Pre-Emptive Capital Raise Secures Runway
Taking advantage of the strong clinical data and commercial momentum, Cytokinetics tapped the favorable macro financing environment to raise $760.1M via an equity offering at $71.00 per share. While dilutive, this strategic move pushes cash reserves to $1.7 billion, ensuring the company can independently fund the global MYQORZO launch and pipeline advancement without relying on immediate profitability.
Other KPIs
Accelerating significantly from $1.1 billion at the end of Q1 2026 and $882 million at the end of 2025. The $760M net proceed injection from the Q2 equity offering provides a fortress balance sheet, essentially eliminating near-term financing risk as the company executes its commercial scale-up.
Decelerating YoY from $110.1 million in 25Q2. The decrease reflects the wind-down of certain clinical trial and supply chain costs compared to 2025, partially offset by higher personnel-related costs. This shows management is successfully pivoting spending weight from R&D toward SG&A.
Wider than the $134.4 million loss in 25Q2, but an improvement sequentially from the $206 million loss in 26Q1. The YoY widening is driven by the drop in high-margin milestone revenues and the surge in SG&A to support the MYQORZO launch.
Guidance
Accelerating. Management raised the prior guidance range of $830-$870M. The $30M bump at the midpoint is attributed to commercial readiness investments prompted by the positive ACACIA-HCM results, signaling aggressive prep for a 2027 nHCM market entry.
Key Questions
European Revenue Dynamics
Of the $2.3M in MYQORZO European revenue recorded in Q2, how much represents initial channel stocking by distributors in Germany versus actual patient demand?
Gross-to-Net Profile
With over 80% of US patients now on paid prescriptions, what is the blended gross-to-net discount looking like, and how do you expect it to evolve as you secure broader commercial coverage?
nHCM Commercial Investments
The FY26 expense guidance was raised specifically for nHCM commercial readiness. Can you detail exactly where these incremental dollars are being allocated, given the target prescriber base largely overlaps with the oHCM market?